Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Current Treatment | Immunology | US/EU | 2023

Login to access report north_east
Contact sales account_box

Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to biosimilar developers. The pipeline of immune biosimilars includes several agents that reference AbbVie’s very successful biologic Humira (adalimumab). Biosimilars of Humira have been available in Europe since October 2018. Biosimilars referencing Roche’s Rituxan / MabThera (rituximab) have also launched in Europe and the United States. As the immune biosimilar space becomes increasingly competitive, it is important that manufacturers and marketers of biosimilars and branded biologics understand the factors that most influence physicians’ choice of therapy. Based on primary market research conducted by Clarivate in the United States, France, and Germany with physicians from two specialties (gastroenterology and rheumatology), clients will gain a clear overview of physicians’ experiences with and attitudes toward biosimilars and understand these drugs’ evolution over the last three years (2021, 2022, and 2023).

Questions answered:

  • Understand current biosimilar use. What are the current levels of experience prescribing biosimilars across different specialties? How do physicians perceive currently available biosimilars?
  • Understand the drivers, barriers, and physicians’ attitudes regarding biosimilar uptake. What are the greatest drivers of/barriers to biosimilar use? How familiar with biosimilars are physicians across different specialties? How similar do physicians perceive biosimilars and reference brands to be? Are physicians aware of the pharmacy-level substitution rules in their own country, and would they expect to prevent this substitution? What are physicians’ opinions of indication extrapolation?
  • Future use. Which types of biosimilar manufacturers do physicians trust most? How will physicians adopt biosimilars initially, and will adoption vary by specialty? Will physician uptake be affected by biosimilar price/reimbursement policies? Will physicians use new biologics once biosimilars are available? How will physicians choose between multiple biosimilars of the same reference product?

Scope:

  • Markets covered: France, Germany, and the United States.
  • Primary research: Survey of 90 rheumatologists and 90 gastroenterologists.

Key companies mentioned:

  • Amgen
  • AbbVie
  • Biogen
  • Celltrion
  • Johnson & Johnson / Janssen
  • Merck & Co. / MSD
  • Mundipharma
  • Novartis / Sandoz
  • Pfizer / Hospira
  • Roche / Genentech
  • Samsung Bioepis

Key drugs mentioned:

  • Remicade (infliximab)
  • Inflectra (infliximab)
  • Remsima (infliximab)
  • Flixabi (infliximab)
  • Enbrel (etanercept)
  • Benepali (etanercept)
  • Nepexto (etanercept)
  • Humira (adalimumab)
  • Amjevita/Amgevita (adalimumab)
  • Idacio (adalimumab)
  • Imraldi (adalimumab)
  • Hukyndra (adalimumab)
  • Hulio (adalimumab)
  • Hyrimoz (adalimumab)
  • Yuflyma (adalimumab)
  • Rituxan / MabThera (rituximab)
  • Truxima (rituximab)
  • Simponi (golimumab)
  • Cimzia (certolizumab pegol)
  • Orencia (abatacept)
  • Actemra / RoActemra (tocilizumab)
  • Stelara (ustekinumab)
  • Entyvio (vedolizumab)
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east